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Background: There is a large Barrett’s esophagus patient population undergoing endoscopic 
surveillance. Methods to stratify patients into higher and lower risk groups may enable more varied 
surveillance intervals for patients with non‐dysplastic Barrett’s esophagus that could optimise use of 
endoscopy resources.  
Objective: We aimed to assess whether risk of progression to esophageal adenocarcinoma differed in 
patients with multiple endoscopic biopsies negative for dysplasia. 
Methods: We conducted a retrospective cohort study among individuals from the population‐based 
Northern Ireland Barrett’s register with a histologically confirmed diagnosis of non‐dysplastic Barrett’s 
esophagus (with intestinal metaplasia) between 1993 and 2010, who had at least one endoscopic 
biopsy conducted at least 12 months after diagnosis. We used Poisson regression to estimate 
incidence rate ratios (IRR) and 95% confidence intervals (CI) for the association between number of 
successive endoscopies showing non‐dysplastic Barrett’s esophagus and risk of esophageal 
adenocarcinoma alone, and combined with high‐grade dysplasia, at the next endoscopy. 
Results: We identified 1,761 individuals who met our eligibility criteria. Subsequent risk of progression 
to esophageal adenocarcinoma was lower at the next endoscopy following two endoscopies showing 
non‐dysplastic Barrett’s esophagus (IRR 0.26, 95% CI 0.10‐0.66) than following one endoscopy 
showing non‐dysplastic Barrett’s esophagus.  Similar findings were apparent for risk of progression to 
esophageal adenocarcinoma or high‐grade dysplasia (IRR 0.41, 95% CI 0.22‐0.79). 
Conclusion: The lower risk of malignant progression in individuals with persistent non‐dysplastic 
Barrett’s esophagus over two consecutive endoscopic biopsies but not for longer term persistence 
does not support hypotheses of persistence being an indicator of less biologically aggressive lesions. 
Instead, the initial difference may be attributable to post‐endoscopy cancers and support the 





1. Summarise the established knowledge on this subject 
 Stratification based on absolute risk of progression to esophageal adenocarcinoma may help 
to tailor surveillance frequency and optimise use of limited endoscopic capacity. 
 However, there are mixed results from previous studies assessing whether risk of 
progression to esophageal adenocarcinoma or dysplasia differs according to the number of 
successive endoscopies with biopsies showing NDBE 
2. What are the significant and/or new findings of this study?  
 Using population based data on histologically confirmed Barrett’s esophagus, we found that 
persistence of NDBE at the first surveillance endoscopy was associated with lower risk of 
progression to esophageal adenocarcinoma at their next endoscopy.  














Barrett’s esophagus is an established pre‐malignant condition of the esophagus that increases risk of 
esophageal adenocarcinoma. The American Gastroenterology Association and British Society of 
Gastroenterology recommend that individuals with non‐dysplastic Barrett’s esophagus (NDBE) receive 
endoscopic surveillance every 3 to 5 years in order to aid early diagnosis and treatment for dysplasia 
or cancer (1,2). As such, there is an increasingly large Barrett’s esophagus patient population 
undergoing endoscopic surveillance(3). However, the cost‐effectiveness of endoscopic surveillance for 
NDBE patients has been questioned (4,5). Stratification based on absolute risk of progression to 
esophageal adenocarcinoma may help to tailor surveillance frequency and optimise use of limited 
endoscopic capacity. 
One potential stratification method could be based on NDBE persistence at multiple endoscopies. A 
recent study by Peters et al found that risk of progression to esophageal adenocarcinoma or high‐
grade dysplasia was reduced in individuals with persistent NDBE within a population‐based cohort (6). 
However, prior evidence has been mixed (7–9). Studies looking at incidence of esophageal cancer in 
NDBE patients have indicated a uniform rate of progression over time (10,11); however, these studies 
did not separate individuals with persistent NDBE from those who have no subsequent endoscopy or 
who progress to dysplasia. 
Therefore, further evidence assessing the potential of persistent NDBE in identifying lower risk 
patients is required. Most evidence published to date has used follow‐up until last 
oesophagogastroduodenoscopy (hereafter referred to as endoscopy) (7,8,12), which leads to 
overlapping follow‐up periods between groups. It may be more informative and clinically relevant to 
assess rate of progression at each endoscopic interval, as this more directly informs how many 
progressions are likely to be detected if surveillance is continued.  
We aimed to investigate whether risk of progression to esophageal adenocarcinoma or dysplasia 
differs according to the number of successive endoscopies with biopsies showing NDBE. We used the 
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population‐based Northern Ireland Barrett’s register (NIBR), which has complete long‐term follow‐up 






The NIBR includes all 13,298 patients diagnosed with Barrett’s esophagus in Northern Ireland from 
January 1993 until December 2010. The methods of the register formation have been previously 
described (10). Briefly, the register was created by reviewing pathology reports of all esophageal 
biopsies (corresponding to SNOMED2 codes T62* and SNOMED3 codes T56*) logged in Northern 
Ireland between 1993 and 2010. A standardised set of guidelines were used for creation of the 
register, and any pathology reports diagnosing histologically confirmed columnar epithelium of the 
esophagus, or synonym terms, were deemed to be Barrett’s esophagus. Patients under 16 years of 
age and reports relating to cancer confined to the oesophagogastric junction were excluded. A subset 
of patients in the NIBR have specialized intestinal metaplasia at biopsy (N=5,150).  
We linked the NIBR to the NI Cancer Registry (NICR) to identify those Barrett’s esophagus patients 
who developed esophageal cancer by the end of 2010. The NICR contains data on all patients 
diagnosed with cancer in Northern Ireland since 1993. The NICR uses the International Classification 
of diseases V.10 (ICD10) to classify patient tumour type and location based on accompanying clinical 
information. ICD10 codes were used to identify patients from the NICR with adenocarcinoma or 
histologically unspecified tumours of the esophagus. Histologically unspecified tumours were included 




The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected 
in a priori ethical approval for the NIBR, NICR and related research granted by the regional ethics 
committee of Northern Ireland (10/NIR01/53, 22nd October 2015). As this is a population‐based Cancer 
Registry study, informed consent is unfeasible but use for research permitted under ethical guidelines 
due to the strict nature of data confidentiality and the ability to withdraw consent (13). The NICR and 
NIBR have strict data confidentiality rules which mean that cell counts less than 5 cannot be revealed. 
As we combine outcomes we were unable to report exact figures less than 10 and cannot report both 
person‐years and incidence rates. 
INCLUSION AND EXCLUSION CRITERIA 
For the current study, we first included only those patients in the NIBR with an index Barrett’s 
esophagus diagnosis date until December 2009 to allow 12 months of follow‐up (Figure 1). For the 
primary analysis, patients with an index biopsy histologically diagnosing NDBE with specialized 
intestinal metaplasia or related terms and at least 1 additional endoscopy with biopsy at least 12 
months later (regardless of findings) were included in this study. Dysplasia or esophageal cancer 
diagnosed within 12 months of the index biopsy were classified as prevalent cases and patients were 
excluded.  
Secondary analyses additionally included NDBE patients without confirmed specialized intestinal 
metaplasia, to reflect clinical practice in the UK (1). 
GROUPING AND OUTCOMES 
Patients were assigned to at least one of five groups (Groups 1 to 5) based on the number of 
endoscopies conducted at least 12 months apart showing NDBE. All 1,761 NDBE patients who met 
the inclusion criteria were included in Group 1. The follow‐up period for Group 1 started at their 
index endoscopy, with the outcome ascertained at their subsequent endoscopy conducted at least 
12 months later. Patients diagnosed with esophageal adenocarcinoma or dysplasia, or those without 
further endoscopies were not included in subsequent groups. Patients with NDBE at the outcome 
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endoscopy for Group 1 (usually their second endoscopy), who also had another subsequent 
endoscopy at least 12 months later, were included in Group 2. To avoid overlapping follow‐up 
periods, follow‐up for Group 2 started from the date of the Group 1 outcome endoscopy until their 
subsequent endoscopy at least 12 months later. The same pattern of eligibility and non‐overlapping 
follow‐up periods were used for subsequent groups. Therefore eligibility for Group 5 required NDBE 
to be demonstrated in at least 5 consecutive endoscopies (including their index endoscopy), with the 
outcome assessed at their subsequent endoscopy. All participants included in Group 5 were also 
included in Groups 1 to 4, but follow‐up periods for each group did not overlap.  
Multiple endoscopies conducted within 12 months may reflect uncertain diagnoses after the initial 
endoscopy, so were classed as one endoscopy using the date of the first endoscopy and the most 
advanced histological diagnosis. Patients were considered to have high‐grade dysplasia, if the 
pathologist reported “high‐grade” or “severe” dysplasia in the endoscopic biopsy sample. 
STATISTICAL ANALYSIS 
The median duration of follow‐up was calculated for each group. Poisson regression models were used 
to calculate incidence rates, rate ratios, and corresponding 95% confidence intervals (CI) for four 
outcomes (i) esophageal adenocarcinoma, (ii) esophageal adenocarcinoma or high‐grade dysplasia, 
(iii) esophageal adenocarcinoma  or any dysplasia, and (iv) dysplasia, according to group (I.e. number 
of endoscopies showing NDBE).  The length of esophageal adenocarcinoma time period contributed 
to the Poisson model “offset” variable. We used the exchangeable working correlation structure to 
account for the correlation among repeated observations for the same subject, after creating multiple 
records for esophageal adenocarcinoma subject by period. Analyses adjusted for age at index 
endoscopy, sex and year of index endoscopy (to account for changes in incidence over time).   
Sensitivity analyses also assessed whether the associations differed when using the broader UK 
definition of BE; and by age; period of qualifying endoscopy; and gender. A priori sensitivity/secondary 
analyses assessed if the results were consistent when follow‐up was continued until last endoscopy 
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or first diagnosis of esophageal adenocarcinoma or high‐grade dysplasia. Esophageal adenocarcinoma 
tumour stage was compared between groups using chi‐squared tests.  




The overall study cohort for the primary analysis included 1,761 patients with histologically confirmed 
Barrett’s esophagus with intestinal metaplasia and no dysplasia or cancer reported at baseline or 
within 12 months. 
Individuals with more consecutive endoscopies showing NDBE were more likely to be male, younger 
aged at their index endoscopy and diagnosed in the earlier years of the registry than individuals with 
fewer consecutive endoscopies showing NDBE (Table 1). 
Subsequent risk of progression to esophageal adenocarcinoma, at the next endoscopy, was 
significantly lower after two consecutive endoscopies showing NDBE (IRR 0.26, 95% CI 0.10‐0.66) than 
after one endoscopy showing NDBE (Table 2). Similar findings were observed for risk of progression 
to esophageal adenocarcinoma or high‐grade dysplasia combined (IRR 0.41, 95% CI 0.22‐0.79, Table 2 
Figure 2) and for risk of progression to esophageal adenocarcinoma or any dysplasia (IRR 0.69, 95% CI 
0.51‐0.92). However, risk of progression was not reduced in subsequent groups with more prior 
endoscopies showing NDBE, except for group 4 who had a reduced risk of esophageal adenocarcinoma 
or dysplasia (IRR 0.42, 95% CI 0.21‐0.87) and dysplasia only (IRR 0.40, 95% CI 0.17‐0.91) compared to 
group 1.  
The reduced risk of progression in group 2 was also apparent when using a broader definition of 
Barrett’s esophagus which includes patients regardless of the presence of specialized intestinal 
metaplasia (IRR 0.38, 95% CI: 0.19‐0.77). The association was also apparent when limited to men (IRR 
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0.31, 95% CI: 0.11‐0.89) and patients aged over 60 at their index endoscopy (IRR 0.08, 95% CI 0.01‐
0.56). The association was weaker, and not statistically significant when follow‐up for esophageal 
adenocarcinoma group was continued until their last endoscopy or progression, as used in previous 




In this population‐based study of histologically confirmed Barrett’s esophagus patients, we found that 
patients with two endoscopies showing NDBE, compared to NDBE on one endoscopy, had an almost 
4 times lower risk of progression to esophageal adenocarcinoma at their next endoscopy. Smaller 
reductions were also apparent when “progression” additionally included HGD or any dysplasia. Results 
for patients with persistent NDBE at a greater number of endoscopies were less clear.  
It has been suggested that surveillance intervals in patients with Barrett’s esophagus, often between 
3‐5 years depending on country (1,14), could be lengthened in patients at a lower risk of progression 
to esophageal adenocarcinoma or dysplasia to optimise use of limited endoscopic capacity (12). Our 
study, conducted within a population with recommended surveillance intervals between 2‐3 years, 
indicates that patients with persistent NDBE at the first surveillance endoscopy were at lower risk of 
subsequent progression to esophageal adenocarcinoma or dysplasia in between endoscopies. This 
result is consistent with previous findings using histologically confirmed NDBE diagnoses from the US 
by Gaddam et al (12) and the Netherlands by Peters et al (8), despite differences in methodological 
approach (described in the strengths and limitations section). Results differed in a prior study (9) 
without histological confirmation of NDBE status, though this may be due to selection bias of high risk 
patients, as evidenced by shorter intervals between successive endoscopies. Therefore, a reduced risk 




The evidence is less clear for individuals with persistent NDBE over a greater number of endoscopies. 
Risk of progression to esophageal adenocarcinoma in individuals with persistent NDBE over the 
greatest number of endoscopies (group 5) were at a similar risk of progression to individuals in the 
reference group, though low numbers preclude firm conclusions. In terms of progression to 
esophageal adenocarcinoma or dysplasia of any grade, which had a larger number of events, a more 
linear trend over groups is apparent and risk of progression was lower in patients with persistent NDBE 
at their third surveillance endoscopy. The corresponding findings from Peters et al (6) are similarly 
mixed, despite consistent results for patients with persistent NDBE at the first surveillance endoscopy. 
Whilst risk of progression reduced with persistent NDBE over a greater number of endoscopies when 
applying a 1 year interval between endoscopies, risk of progression increased with NDBE persistence 
when applying shorter interval criteria (<1 year).  
It is possible that the mixed results in the current study are attributable to reduced statistical power 
as the number of events was low and selection bias towards higher risk patients for continued 
surveillance (though the similar follow‐up periods between groups are reassuring). The reduced risk 
of progression following two consecutive endoscopic biopsies displaying NDBE could be attributable, 
in part, to a reduced risk of post‐endoscopy cancers. It has been estimated from the NIBR and in other 
cohorts (15,16) that ~10% of esophageal adenocarcinomas may be post‐endoscopy cancers some of 
which may have been present but undetected at the first endoscopic biopsy. These false‐negative 
lesions may inflate the progression rate in the first group as they are more likely to be detected at the 
first surveillance endoscopy, whereas fewer false‐negatives are likely to be present at subsequent 
endoscopies. Therefore, these mixed results may highlight the challenges faced in detecting malignant 
lesions at the initial index endoscopy and the need to adhere to robust quality standards (17), 
published after the study period. Similarly, early repeat endoscopy, if the index endoscopy does not 
meet quality standards in terms of visualisation or biopsy protocol, may be beneficial to reduce post‐
endoscopy lesions (17). 
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The subsequent pattern of results does not offer strong support for the hypothesis that persistent 
NDBE reflects more stable, less biologically aggressive disease, and instead may indicate a steady rate 
of progression, which is consistent with findings based on clonal diversity (18,19) and studies looking 
at progression over time (10). Similarly, when using follow‐up from the qualifying endoscopy for each 
group until either the outcome developed or the last endoscopy recorded within the study period 
(rather than the next endoscopy), no reductions in risk of progression were apparent in patients with 
persistent NDBE.  
Whilst it is possible that dysplasia/cancer diagnosis increased over time as prevalence of risk factors 
like obesity may have changed, we adjusted for cohort effects through year of BE diagnosis and prior 
analyses from other UK cohorts didn’t find evidence of time period effects as incidence of 
dysplasia/cancer in surveillance endoscopies was stable over time (1995‐2009) (World J 
Gastroenterol. 2016 Dec 28; 22(48): 10592–10600). 
Strengths & limitations 
In addition to the robust methodology, this study had a number of strengths. The cohort is from a 
population‐based register, enabling capture of all cancers and histologically confirmed Barrett’s 
esophagus cases in a defined area, with low migrations rates (20). Additionally, intervals between 
endoscopies remained constant across each group suggesting that high‐risk patients were not 
preferentially selected for more regular endoscopic surveillance, though as indicated earlier may have 
been selected for longer term surveillance. Unlike previous studies that calculated risk of progression 
over the remaining follow‐up period, our primary analysis calculated risk at the next endoscopy to 
avoid overlapping follow‐up periods between groups, and to better quantify the likelihood of 
detecting esophageal adenocarcinoma at each subsequent endoscopy. Our study also avoided using 
mutually exclusive selection, unlike a previous study (7), to reduce risk of inflating progression in the 
non‐persistent NDBE group by excluding non‐progressors eligible for later groups. 
There are also some potential limitations to consider. The statistical power to detect differences 
between groups 3‐5 and group 1 was limited, which prevents firm conclusions regarding the incidence 
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in these patients. The follow‐up period was limited due to availability of data on subsequent 
endoscopies after 2010. Since the study includes data between 1993 and 2010, it is possible that the 
data reflects historic endoscopic practices and that patterns of post‐endoscopy lesions may have 
changed following changes to endoscopic guidelines and quality standards (15). Adherence to 
protocols may have changed over time, which could lead to improved detection in later groups, 
though unfortunately information on adherence was not available. Nevertheless, the results of the 
current study reflect real world practices and prior evidence suggests that rates of post‐endoscopy 
cancers in the NIBR did not change between 1993 and 2013 (15). Similarly patterns of dysplasia 
diagnosis may have changed, or since the study period due to the introduction of endoscopic mucosal 
resection and radiofrequency ablation. 
Information on Barrett’s segment length was not always available, which meant stratification based 
on Barrett’s length was not possible, which is a limitation given that risk of progression is known to be 
higher in long‐segment Barrett’s (10,21).  
Risk of progression may be influenced by age, time of outcome assessment (period) or time of BE 
diagnosis (cohort). We were able to adjust for age and time of diagnosis, however, as we needed to 
offset by person‐years, we were unable to additionally adjust for time of outcome assessment. 
Therefore, the later time period of outcome endoscopies in later groups could partially explain the 
lack of a reduced risk of progression. Nevertheless prior analyses in other UK Barrett’s esophagus 
cohorts didn’t indicate time period effects between 1995‐2005 (21). 
The proportion of NDBE patients with at least 1 year of endoscopic follow‐up with biopsy was low 
(~37%), in part due to limited follow‐up time available for individuals diagnosed post‐2007. This may 
lead to selection bias due to symptomatic presentation as information on reason for endoscopy was 
unavailable. The selection bias may primarily impact the non‐persistent NDBE group, as non‐
surveillance attenders who do not progress and do not undergo endoscopy would have been 
excluded, whereas non‐surveillance attenders who progress and had an endoscopy for symptomatic 
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presentation would have been included. We attempted to limit the impact of symptomatic 
presentation by conducting a sensitivity analysis excluding individuals with over 5 years of follow‐up 
between endoscopies, which did not materially change the estimates and may alleviate these 
concerns. 
Conclusion 
This study adds to the body of evidence suggesting that in patients with persistent NDBE at their first 
surveillance endoscopy, risk of subsequent progression to esophageal adenocarcinoma or dysplasia in 
between surveillance endoscopies is lower. However, the evidence for a reduced risk of progression, 
in patients with persistent NDBE over a greater number of endoscopies is less clear. Further evidence 
will likely be required before recommendations to extend surveillance intervals for subsequent 
surveillance periods can be supported. The high incidence at the first surveillance endoscopy, may be 
indicative of undetected lesions at the initial index endoscopy, which indicates the need for high‐
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Table 1. Participant characteristics by group 
 Group 1 Group 2 Group 3 Group 4 Group 5 
 (n=1761) (n=840) (n=399) (n=173) (n=88) 
Age at NDBE diagnosis (mean) 58.44 57.03 56.79 55.03 54.14 
Men (%) 65.0% 65.6% 67.3% 71.2% 73.3% 
Mean calendar year of NDBE 
diagnosis 
2000 1998 1997 1996 1995 
Mean calendar year of 
qualifying endoscopy 1 
2000 2000 2001 2001 2002 
Median years follow‐up until 
next endoscopy 
1.98 2.01 1.99 1.91 1.96 
1 Start of follow‐up period in each group. 
















Table 2. Incidence rate and incidence rate ratios of progression by number of prior upper 
endoscopies showing NDBE. 




per 100 PY 
 Adjusted1 
 IRR (95% CI) 
Esophageal adenocarcinoma     
Group 1 2 1761 42 1.02  1.00 (Referent) 
Group 2 840 <103 0.27  0.26 (0.10‐0.66) 
Group 3 399 <10 0.72  0.65 (0.27‐1.56) 
Group 4 173 <10 0.61  0.53 (0.12‐2.24) 
Group 5 88 <10 1.22  1.04 (0.24‐4.50) 
Esophageal adenocarcinoma/HGD 
Group 1 1761 60 1.45  1.00 (Referent) 
Group 2 840 11 0.59  0.41 (0.22‐0.79) 
Group 3 399 10 1.20  0.82 (0.41‐1.63) 
Group 4 173 <10 0.61  0.41 (0.10‐1.71) 
Group 5 88 <10 1.22  0.83 (0.20‐3.51) 
Esophageal adenocarcinoma/Dysplasia 
Group 1 1761 179 4.34  1.00 (Referent) 
Group 2 840 60 3.22  0.69 (0.51‐0.92) 
Group 3 399 35 4.20  0.81 (0.56‐1.17) 
Group 4 173 <10 2.44  0.42 (0.21‐0.87) 
Group 5 88 <10 2.44  0.41 (0.15‐1.11) 
Dysplasia      
Group 1 1761 137 3.32  1.00 (Referent) 
Group 2 840 55 2.95  0.81 (0.59‐1.11) 
Group 3 399 29 3.48  0.86 (0.57‐1.30) 
Group 4 173 <10 1.83  0.40 (0.17‐0.91) 
Group 5 88 <10 1.22  0.25 (0.06‐1.04) 
1 Poisson model adjusted for age at BE diagnosis, sex and year of BE diagnosis 
2 Group number reflects number of endoscopies (more than 12 months apart) showing non‐dysplastic 
Barrett’s esophagus. 
3 Small numbers reported as <10 to avoid disclosing cell counts <5 for data confidentiality purposes. 




Table 3. Adjusted1 incidence rate ratios by group based on sensitivity analyses 
    Group 12 Group 2 Group 3 Group 4 Group 5 
UK definition N 2541 1133 524 222 112 IRR 1.00 (Referent) 0.38 (0.19‐0.77) 0.55 (0.23‐1.30) 0.44 (0.11‐1.85) 1.32 (0.40‐4.40) 
Men only N 1146 552 268 124 65 IRR 1.00 (Referent) 0.31 (0.11‐0.89) 0.48 (0.14‐1.62) 0.37 (0.05‐2.81) 0.72 (0.09‐5.55) 
Under 60 at index N 930 471 224 107 54 IRR 1.00 (Referent) 0.67 (0.21‐2.10) 1.06 (0.28‐3.97) 0.77 (0.09‐6.37) Not calculable 
Over 60 at index N 831 369 175 66 34 IRR 1.00 (Referent) 0.08 (0.01‐0.56) 0.47 (0.14‐1.59) 0.42 (0.06‐3.16) 1.58 (0.36‐7.06) 
Diagnosis pre‐2000 N 991 347 89 14 <10 IRR 1.00 (Referent) 0.39 (0.09‐1.72) 2.32 (0.65‐8.29) Not calculable Not calculable 
Interval <5 years N 1651 809 386 172 88 IRR 1.00 (Referent) 0.33 (0.10‐1.11) 1.19 (0.43‐3.29) 1.23 (0.27‐5.63) 2.53 (0.54‐11.90) 
Follow‐up until last EGD 
N 1761 840 399 173 88 
IRR 1.00 (Referent) 0.91 (0.75‐1.10) 0.90 (0.70‐1.16) 0.90 (0.63‐1.28) 0.89 (0.55‐1.42) 
1 Poisson model adjusted for age at BE diagnosis, sex and year of BE diagnosis 









Figure 1. Flow chart of participant selection 
Abbreviations: NDBE: Non‐dysplastic Barrett’s esophagus; NIBR=Northern Ireland Barrett’s Register. 
Figure 2. Adjusted incidence rate ratios and 95% confidence intervals for progression from NDBE to 
esophageal adenocarcinoma or high‐grade dysplasia by number of prior upper endoscopies showing 
NDBE. 
1 Poisson model adjusted for age at BE diagnosis, sex and year of BE diagnosis 
2 Group number reflects number of endoscopies (more than 12 months apart) showing non‐dysplastic 
Barrett’s esophagus. Outcome assessed at subsequent endoscopy at least 12 months later. Group 1, 
from index endoscopy showing NDBE is the reference category. 
3 Patients included in later groups were also included in previous groups. 
 
 
 
 
 
 
 
 
 
 
 
 
